Quality & Reliability A.B.E.E. (ATH:QUAL)

Oncternal Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	15.17	10.35	6.46	2.95	2.92
Revenue Growth (YoY)	46.62%	60.27%	119.09%	1.01%	28.37%
Cost of Revenue	10.33	6.7	4.46	2.14	2.11
Gross Profit	4.84	3.65	2	0.81	0.8
Selling, General & Admin	2.8	2.18	1.59	1.06	0.97
Other Operating Expenses	0.46	0.34	0.01	0	-
Operating Expenses	3.26	2.52	1.6	1.07	0.97
Operating Income	1.58	1.13	0.4	-0.26	-0.17
Interest Expense	-0.58	-0.41	-0.2	-0.26	-0.17
Interest & Investment Income	0	0	0	0	0
Other Non Operating Income (Expenses)	-0.25	-0.23	-0.16	-0.04	-0.05
EBT Excluding Unusual Items	0.76	0.49	0.04	-0.56	-0.39
Gain (Loss) on Sale of Assets	-	-	-	0	-
Asset Writedown	0.02	-0	0.02	0.01	-0.06
Other Unusual Items	-	-	-	-	-0.16
Pretax Income	0.77	0.49	0.07	-0.55	-0.61
Income Tax Expense	0.44	-0.15	0.06	0.08	0.06
Earnings From Continuing Operations	0.33	0.63	0.01	-0.63	-0.66
Net Income	0.33	0.63	0.01	-0.63	-0.66
Net Income to Common	0.33	0.63	0.01	-0.63	-0.66
Net Income Growth	-48.01%	11704.73%	-	-	-
Shares Outstanding (Basic)	27	27	27	27	27
Shares Outstanding (Diluted)	27	27	27	27	27
EPS (Basic)	0.01	0.02	0.00	-0.02	-0.02
EPS (Diluted)	0.01	0.02	0.00	-0.02	-0.02
EPS Growth	-48.01%	11750.26%	-	-	-
Free Cash Flow	2.28	-0.79	-0.7	-0.28	-0.4
Free Cash Flow Per Share	0.08	-0.03	-0.03	-0.01	-0.01
Gross Margin	31.90%	35.25%	30.92%	27.34%	27.57%
Operating Margin	10.43%	10.88%	6.18%	-8.87%	-5.80%
Profit Margin	2.17%	6.11%	0.08%	-21.43%	-22.78%
Free Cash Flow Margin	15.02%	-7.64%	-10.87%	-9.55%	-13.77%
EBITDA	2.11	1.46	0.48	-0.21	-0.14
EBITDA Margin	13.91%	14.06%	7.46%	-7.28%	-4.84%
D&A For EBITDA	0.53	0.33	0.08	0.05	0.03
EBIT	1.58	1.13	0.4	-0.26	-0.17
EBIT Margin	10.43%	10.88%	6.18%	-8.87%	-5.80%
Effective Tax Rate	57.47%	-	91.92%	-	-

Updated Sep 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.